Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003748 · ClinicalTrials.gov registry record · Phase 2

Irinotecan in Treating Patients With Esophageal or Stomach Cancer

A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
20
Study locations

NCT00003748 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003748, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or stomach cancer.

Conditions Studied

Gastric Cancer Esophageal Cancer

Interventions

  • DRUG irinotecan hydrochloride

Study Locations (20)

California

  • Comprehensive Blood and Cancer Center - Bakersfield
  • St Jude Heritage Health Foundation - Fullerton
  • Daniel Freeman Memorial Hospital - Inglewood
  • UCLA - Antelope Valley Cancer Center - Lancaster
  • Pacific Shores Medical Group - Long Beach
  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
  • Community Hospital of the Monterey Peninsula - Monterey
  • Office of Jerome L. Rubin - Monterey
  • Office of Eddie Hu, M.D. - Monterey Park
  • Ventura County Hematology-Oncology Medical Group, Inc. - Oxnard
  • Wilshire Oncology Medical Center - Pomona
  • Salinas Valley Memorial Hospital - Salinas
  • Cancer Center of Santa Barbara - Santa Barbara
  • Sansum Medical Clinic - Santa Barbara
  • James L. Poth, M.D., Michael Alexander, M.D., Inc. - Santa Cruz
  • Marian Medical Center - Santa Maria
  • Office of Marilou Terpenning - Santa Monica
  • Office of Robert C. Klein - Santa Monica
  • Dominican and Watsonville Community Hospital - Soquel
  • Los Robles Regional Medical Center - Thousand Oaks

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1998-08
Est. Completion 2005-01
Phase Phase 2

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003748

The ClinicalTrials.gov registry entry for NCT00003748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which irinotecan hydrochloride is the first listed.

NCT00003748 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00003748 about?

NCT00003748 is a clinical study titled "Irinotecan in Treating Patients With Esophageal or Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or stomach cancer.

What is the current status of trial NCT00003748?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1998-08. Estimated completion is 2005-01.

What conditions does trial NCT00003748 study?

This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT00003748?

The interventions under investigation include: irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003748?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003748 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Esophageal Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.